Detection method of loxoprofen sodium gel plaster related substances

Through high-performance liquid chromatography, specific chromatographic conditions and diluents are used to optimize the elution procedure, and the problem of poor impurity separation and peak shape in the detection of loxoprofen sodium gel paste is solved, achieving high-efficiency substances Test to ensure the quality and safety of drugs.

CN119064487APending Publication Date: 2024-12-03江苏济茗医药有限公司
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202410393925.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing substance detection methods for loxoprofen sodium gel paste cannot effectively separate unknown impurities and known impurities, and the sensitivity and peak shape are not good enough, which affects the quality and safety of the drug.

Method used

High performance liquid chromatography is used to use specific chromatographic columns, mobile phases and detection wavelength conditions, including the use of octadecylsilane bonded silica gel chromatography columns, 0.02mol/L sodium dihydrogen phosphate solution and acetonitrile as mobile phases, combined with methanol Diluent, optimize elution procedures to improve the resolution and peaking of impurities.

Benefits of technology

It has achieved efficient quantitative detection of substances related to loxoprofen sodium gel paste, with good separation between each impurity, good peak shape, and gentle baseline fluctuations, which solved the problem of insufficient sensitivity and resolution in the original method.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119064487A_ABST
    Figure CN119064487A_ABST
Patent Text Reader

Abstract

The invention belongs to the field of drug detection, and relates to a loxoprofen sodium gel plaster related substance detection method, which comprises: carrying out quantitative detection on loxoprofen sodium gel plaster related substances by using high performance liquid chromatography, high performance liquid chromatography conditions are as follows: a chromatographic column uses octadecylsilane chemically bonded silica as a filler; a mobile phase A is a 0.02 mol / L sodium dihydrogen phosphate solution (the pH value is 2.9); a mobile phase B is acetonitrile; the flow rate is 0.9 ml / min; the column temperature is 20 DEG C; the detection wavelength is 222nm; and the diluent is methanol. According to the chromatographic conditions provided by the invention, the separation degree between the impurities and the main peak is good, the peak pattern is good, the baseline fluctuation is smooth, and the peak pattern and the separation degree of the impurities are both improved compared with those of the primary chromatographic conditions.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of drug detection and relates to a method for detecting related substances in a loxoprofen sodium gel patch. Background Art

[0002] Loxoprofen sodium gel is a topical preparation containing loxoprofen sodium, a nonsteroidal anti-inflammatory drug (NSAID). Its primary function is to reduce inflammation and relieve pain. It has excellent anti-inflammatory and analgesic effects for acute and chronic inflammation, as well as pain. Therefore, it is commonly used to treat conditions such as osteoarthritis, muscle pain, and swelling and pain caused by trauma.

[0003] The control of related substances in a product is crucial to its quality. Currently, the only detection method for related substances in loxoprofen sodium gel patch is the standard of the raw material manufacturer. However, after the inventors reproduced the method, they found that the manufacturer's method could not effectively separate unknown impurities and all known impurities, and had problems such as insufficient sensitivity and peak shape. In order to ensure the quality of the preparation during research, production, storage, sales and use, and to ensure the safety and effectiveness of the drug, it is urgently necessary to provide a detection method with high sensitivity and good separation between impurities. Summary of the Invention

[0004] To solve the above technical problems, the present invention provides a method for detecting related substances in loxoprofen sodium gel patch. The chromatographic conditions of the present invention are compared with the standard chromatographic conditions provided by the raw material manufacturer. Both the peak shape and separation of impurities are improved compared with the original chromatographic conditions.

[0005] There are 8 known impurities that may be contained in the final product of loxoprofen sodium gel patch:

[0006]

[0007]

[0008] The technical solutions provided by the present invention are as follows:

[0009] A method for detecting related substances in a loxoprofen sodium gel patch comprises the following steps:

[0010] High performance liquid chromatography was used to quantitatively detect the related substances in loxoprofen sodium gel patch;

[0011] HPLC conditions included:

[0012] Chromatographic column: Use octadecylsilane bonded silica gel as filler (Shim-pack GIST C18, 4.6 mm × 250 mm, 5 μm or a column of equivalent performance);

[0013] Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution (take 2.4 g of sodium dihydrogen phosphate, dilute to 1000 ml with water, and adjust the pH to 2.9 ± 0.1 with phosphoric acid);

[0014] Mobile phase B: acetonitrile;

[0015] Flow rate: 0.8~1.0ml / min;

[0016] Detection wavelength: 222nm;

[0017] The injection volume was 20 μl;

[0018] Diluent: methanol.

[0019] Furthermore, the elution procedure is as follows:

[0020]

[0021]

[0022] Furthermore, the related substances are impurity I, impurity II, impurity III, impurity III, impurity IV, impurity V, impurity VI, impurity VII, and impurity X.

[0023] Furthermore, the test solution and the system suitability solution were respectively injected into a liquid chromatograph, and the chromatograms were recorded. The test solution and the system suitability solution were prepared as follows:

[0024] Loxoprofen sodium reference substance, impurity I, impurity II, impurity III, impurity IV, impurity V, impurity VI, impurity VII, and impurity X reference substance were dissolved in methanol by ultrasonication, and then diluted to prepare a solution containing 0.5 mg of loxoprofen sodium, 15 μg of impurity I, 6.5 μg of impurity II, 2.5 μg of impurity III, impurity IV, impurity V, impurity VI, impurity VII, and 7.5 μg of impurity X per 1 ml; this was used as the system suitability solution;

[0025] Take about 2.5g of the paste to be tested, weigh it accurately, put it in a beaker, add 50ml of methanol, homogenize it with a homogenizer at 8000rpm for 10 minutes, seal it and ultrasonicate it for 60 minutes, centrifuge it to take the supernatant, and then filter it to take the filtrate.

[0026] Furthermore, the test solution was diluted 100 times with a diluent to serve as a 1% self-control solution.

[0027] Furthermore, the color spectrum is recorded, and the content of individual impurities and total impurities is calculated using the self-control method.

[0028] Furthermore, the calculation method of individual impurities and total impurities is:

[0029] Single impurity % = single impurity peak area / control peak area * 1%;

[0030] Total impurities % = sum of impurity peak areas / control peak area * 1%.

[0031] Furthermore, the injection volume was 20 μl.

[0032] Furthermore, the column temperature is 19-21°C.

[0033] A method for detecting related substances in a loxoprofen sodium gel patch comprises the following steps:

[0034] (1) Solution preparation:

[0035] Solvent: methanol;

[0036] Take loxoprofen sodium reference substance, impurity I, impurity II, impurity III, impurity IV, impurity V, impurity VI, impurity VII, and impurity X reference substances, add methanol and ultrasonically dissolve them, then dilute to prepare a solution containing 0.5 mg of loxoprofen sodium, 15 μg of impurity I, 6.5 μg of impurity II, 2.5 μg of impurity III, impurity IV, impurity V, impurity VI, impurity VII, and 7.5 μg of impurity X per 1 ml; use this as the system suitability solution;

[0037] Take about 2.5g of the paste of this product, weigh it accurately, put it in a beaker, add 50ml of methanol, homogenize it with a homogenizer at 8000rpm for 10 minutes, seal it and ultrasonicate it for 60 minutes, centrifuge it to take the supernatant, and then filter it to take the filtrate.

[0038] (2) Chromatographic conditions:

[0039] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV

[0040] Chromatographic column Shim-pack GIST C18, 4.6 mm × 250 mm, 5 μm;

[0041] Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution (take 2.4 g of sodium dihydrogen phosphate, dilute to 1000 ml with water, and adjust the pH to 2.9 ± 0.1 with phosphoric acid);

[0042] Mobile phase B: acetonitrile;

[0043] Flow rate: 0.9 ml / min;

[0044] Column temperature: 20°C;

[0045] Detection wavelength: 222nm;

[0046] The injection volume was 20 μl;

[0047] The elution program is as follows:

[0048]

[0049] (3) Determination: Take 20 μl of the test solution and system suitability solution respectively and inject them into the liquid chromatograph, and record the chromatogram.

[0050] Beneficial effects

[0051] The present invention provides for the first time an optimized method for detecting related substances in loxoprofen sodium gel patch. The provided chromatographic conditions have good separation between impurities and the main peak, good peak shape, and gentle baseline fluctuation. Both the peak shape and separation of the impurities are improved compared with the original chromatographic conditions. BRIEF DESCRIPTION OF THE DRAWINGS

[0052] Figure 1 This is the solution chromatogram for the test method - system suitability;

[0053] Figure 2 The chromatogram of the solution for the system suitability under the two chromatographic conditions of the test method is shown;

[0054] Figure 3 Chromatogram of blank excipient solution under the second chromatographic conditions of the detection method;

[0055] Figure 4 The chromatogram of the solution under the three chromatographic conditions of the test method - system suitability;

[0056] Figure 5 Chromatogram of blank excipient solution under the chromatographic conditions of detection method three;

[0057] Figure 6 The chromatogram of the solution for system suitability under the chromatographic conditions of the fourth test method;

[0058] Figure 7 This is the chromatogram of the blank excipient solution under the chromatographic conditions of detection method four.

[0059] Figure 8 This is the solution chromatogram of the system suitability under the chromatographic conditions of detection method V.

[0060] Figure 9 The figure shows the solution chromatogram of the system suitability under the six chromatographic conditions of the detection method. DETAILED DESCRIPTION

[0061] Example 1

[0062] Detection method 1 for related substances in loxoprofen sodium gel patch:

[0063] (1) Solution preparation:

[0064] Solvent (diluent): 80% methanol;

[0065] Mother liquor of each impurity: Weigh 1 mg of each impurity and place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale.

[0066] System suitability solution: Weigh 3.03 mg of loxoprofen sodium working reference into a 10 ml volumetric flask, add 100 μl of each impurity mother solution, and dilute to the mark with 80% methanol.

[0067] Test solution: Weigh 1.5592 g of homemade loxoprofen sodium sample into a 150 ml beaker, add 60 ml of solvent (80% methanol) and use a homogenizer (8000 r / min) to make a suspension. Add about 40 ml of solvent to clean the homogenizer rod and beaker, transfer the solution to the same volumetric flask, dilute to the scale, shake well, centrifuge (8000 r / min) and collect the supernatant.

[0068] Blank auxiliary solution: 2.0248 g of blank auxiliary material is placed in a 150 ml beaker, 60 ml of solvent is added and a suspension is made using a homogenizer (8000r10min). The homogenizer rod and beaker are cleaned with about 40 ml of solvent. The solution is transferred to the same volumetric flask, diluted to the scale, shaken and centrifuged (8000r10min), and the supernatant is obtained.

[0069] (2) Chromatographic conditions:

[0070] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV

[0071] Chromatographic column: 4.6*250mm, 5μm, filled with octadecylsilane bonded silica gel;

[0072] Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution (pH 3.0);

[0073] Mobile phase B: acetonitrile;

[0074]

[0075] Flow rate: 1.0 ml / min;

[0076] Column temperature: 20°C;

[0077] Detection wavelength: 222nm;

[0078] The injection volume was 20 μl;

[0079] (3) Determination: Take 20 μl of each of the solvent, test solution, air auxiliary solution and system suitability solution and inject them into the liquid chromatograph. Record the chromatogram. Typical spectra are shown in Figure 1 .

[0080] (4) Result: Figure 1 It can be seen from the spectrum that the separation of impurity I (12.980min) and impurity IV (12.739min) in the system solution is not enough, with a separation degree of 1.057. The chromatographic conditions were optimized and the gradient was adjusted.

[0081] Example 2

[0082] Method 2 for the detection of related substances in loxoprofen sodium gel patch:

[0083] (1) Solution preparation: Prepare the solution in the same manner as in Example 1.

[0084] (2) Chromatographic conditions:

[0085] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV

[0086] Chromatographic column: 4.6*250mm, 5μm, filled with octadecylsilane bonded silica gel;

[0087] Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution (pH 3.0);

[0088] Mobile phase B: acetonitrile

[0089]

[0090] Flow rate: 1.0 ml / min;

[0091] Column temperature: 20°C;

[0092] Detection wavelength: 222nm;

[0093] The injection volume was 20 μl;

[0094] (3) Determination: Take 20 μl of each of the solvent, blank excipient solution, system suitability solution and test solution and inject them into the liquid chromatograph. Record the chromatogram. Typical spectra are shown in Figure 2 、 Figure 3 .

[0095] (4) Results: Figure 2 、 Figure 3 As shown in the figure, under the gradient conditions, the excipient peak of the blank excipient solution interferes with the main component, and the gradient optimization is continued.

[0096] Example 3

[0097] Detection method three for related substances in loxoprofen sodium gel patch:

[0098] (1) Solution preparation: Prepare the solution in the same manner as in Example 1.

[0099] (2) Chromatographic conditions:

[0100] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV

[0101] Chromatographic column: 4.6*250mm, 5μm, filled with octadecylsilane bonded silica gel;

[0102] Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution (pH 3.0);

[0103] Mobile phase B: acetonitrile;

[0104]

[0105]

[0106] Flow rate: 1.0 ml / min;

[0107] Column temperature: 20°C;

[0108] Detection wavelength: 222nm;

[0109] The injection volume was 20 μl;

[0110] (3) Determination: Accurately measure the solvent, air auxiliary solution, system suitability solution and test solution, inject them into the liquid chromatograph respectively, and record the chromatogram. The typical spectrum is shown in Figure 4 .

[0111] (4) Results: Figure 4-Figure 5 As shown in the graph, it can be seen that under the gradient conditions, the air-assisted solution has no interference with known impurities and unknown impurities, and the flow rate is further adjusted for investigation.

[0112] Example 4

[0113] Detection method 4 for related substances in loxoprofen sodium gel patch:

[0114] (1) Solution preparation:

[0115] Solvent: methanol.

[0116] Mother liquor of each impurity: Weigh 1 mg of each impurity and place it in a 10 ml volumetric flask, add solvent to dissolve and dilute to the scale.

[0117] System suitability solution: Accurately weigh 5.85 mg of the working reference substance and place it in a 10 ml volumetric flask. Dissolve it in methanol. Add 1.5 ml of the impurity mother solution of impurity I, 650 μl of impurity II, 250 μl of impurity III, impurity IV, impurity V, impurity VI, and impurity VII, respectively, and dilute to the mark.

[0118] Blank excipient solution: Weigh 2.5029 g of blank paste and add 50 ml of methanol to homogenize (8000 rpm for 10 min). Seal the solution and ultrasonicate for 1 h at an ultrasonic power of 100 W. Shake well and centrifuge to obtain the supernatant.

[0119] Test spiked solution: weigh 2.50949 g of the paste into a beaker, quantitatively add 50 ml of methanol, homogenize (8000 rpm for 10 min), seal the solution and sonicate for 1 h, shake and centrifuge, take 5 ml of the supernatant and add 750 μl of each impurity mother liquor, impurity I, 325 μl of impurity II, 125 μl of impurity III, impurity IV, impurity V, impurity VI, and impurity VII respectively, and mix well.

[0120] (2) Chromatographic conditions:

[0121] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV

[0122] Chromatographic column: 4.6*250mm, 5μm, filled with octadecylsilane bonded silica gel;

[0123] Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution (pH 3.0);

[0124] Mobile phase B: acetonitrile;

[0125]

[0126] Flow rate: 0.9 ml / min;

[0127] Column temperature: 20°C;

[0128] Detection wavelength: 222nm;

[0129] The injection volume was 20 μl;

[0130] (3) Determination: Accurately measure the solvent, blank excipient solution and test spiked solution and inject them into the liquid chromatograph respectively, and record the chromatogram. Typical chromatograms are shown in Figure 6 .

[0131] (4) Results: See Figure 6 、 Figure 7 As shown in the graph, under the gradient conditions, a flow rate of 0.9 ml / min provides good resolution between the known and unknown impurities in the spiked test solution, so a flow rate of 0.9 ml / min was selected. This chromatographic condition is feasible.

[0132] Example 5

[0133] Detection method 5 for impurity X increased by related substances in loxoprofen sodium gel patch:

[0134] (1) Solution preparation:

[0135] Impurity X solution: Weigh 1.179 mg of impurity X into a 20 ml volumetric flask, add methanol to dissolve and dilute to the mark.

[0136] System suitability solution: Accurately weigh 4.996 mg of the working reference substance in a 10 ml volumetric flask and dissolve it in methanol. Add 1.5 ml of the impurity mother solution of impurity I, 650 μl of impurity II, 250 μl of impurity III, impurity IV, impurity V, impurity VI, and impurity VII, and 1 ml of the impurity X solution, and dilute to the mark with methanol.

[0137] (2) Chromatographic conditions: same as in Example 4.

[0138] (3) Determination: Take the above solutions and inject them into the liquid chromatograph, and record the chromatogram. Typical chromatograms are shown in Figure 8 .

[0139] (4) Results: See Figure 8 As shown in the graph, it can be seen that under the gradient conditions, the impurity X impurity is increased and the separation degree is good under the chromatographic conditions.

[0140] Example 6

[0141] Method 6 for optimizing mobile phase pH value of related substances of loxoprofen sodium gel patch:

[0142] (1) Solution preparation:

[0143] Impurity I stock solution: Take about 3.75 mg of the impurity I reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0144] Impurity II stock solution: Take about 1.625 mg of impurity II reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve and dilute to the scale, and shake well.

[0145] Impurity III stock solution: Take about 2 mg of impurity III reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0146] Impurity IV stock solution: Take about 2 mg of impurity IV reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0147] Impurity V stock solution: Take about 2 mg of impurity V reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0148] Impurity VI stock solution: Take about 2 mg of impurity VI reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0149] Impurity VII stock solution: Take about 2 mg of impurity VI reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0150] Impurity X stock solution: Take about 1.875 mg of the impurity X reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0151] Impurity mixed stock solution: Accurately measure 5 ml each of impurity III stock solution, impurity IV stock solution, impurity V stock solution, impurity VI stock solution, and impurity VII stock solution, place them in a 50 ml volumetric flask, dilute to the scale with methanol, and shake well.

[0152] System suitability solution: Take about 25 mg of loxoprofen sodium reference substance, accurately weigh it, and place it in a 50 ml volumetric flask. Accurately add 2 ml each of impurity I stock solution, impurity II stock solution, and impurity X stock solution, dilute to the scale with methanol, and shake well.

[0153] Stock solution of spiked test sample: Take about 2.5 g of the product paste, weigh it accurately, and place it in a beaker. Then accurately add 2 ml each of impurity I stock solution, impurity II stock solution, impurity X stock solution, and 5 ml of impurity mixed stock solution, add 39 ml of methanol, homogenize with a homogenizer at 8000 rpm for 10 minutes, seal the container and sonicate for 60 minutes, take an appropriate amount of solution, centrifuge, take the supernatant and filter to obtain the filtrate.

[0154] (2) Chromatographic conditions:

[0155] Instrument: Shimadzu LC-2030C-PLUS; Detector: UV

[0156] Chromatographic column: 4.6*250mm, 5μm, filled with octadecylsilane bonded silica gel;

[0157] Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution (pH 2.9);

[0158] Mobile phase B: acetonitrile

[0159]

[0160] Flow rate: 0.9 ml / min;

[0161] Column temperature: 20°C;

[0162] Detection wavelength: 222nm;

[0163] The injection volume was 20 μl

[0164] (3) Determination: Accurately measure the blank solvent (diluent), system suitability solution, and spiked test solution, inject them into the liquid chromatograph respectively, and record the chromatogram.

[0165] (4) Results: As shown in Figure 9, the separation is good under this chromatographic condition. This chromatographic condition is feasible.

[0166] (5) Conclusion: The separation degree of Example 6 is greater than that of Example 1 by more than 1.5, and there is no blank interference in comparison with Example 2, and the separation degree is better than that of Examples 3 and 4.

[0167] Example 7

[0168] Extraction investigation method for related substances of loxoprofen sodium gel patch seven:

[0169] (1) Solution preparation:

[0170] Blank solvent (diluent): methanol

[0171] System suitability solution: same as the solution in Example 6.

[0172] Test solution: Accurately weigh about 2.5 g of sample paste and place it in a 150 ml beaker. Add 50 ml of methanol and homogenize with a homogenizer (8000 rpm). After 10 minutes, seal the solution, ultrasonicate for 15 minutes, 30 minutes, and 60 minutes respectively, shake well, and centrifuge (8000 rpm, 10 minutes) to obtain the supernatant.

[0173] (2) Chromatographic conditions: Same as Example 6.

[0174] (3) Determination: Accurately measure the blank solvent, system suitability solution, and test solution, inject them into the liquid chromatograph, and record the chromatogram. The data are shown in Table 1 below:

[0175] Table 1 Method development for related substances - investigation of sample extraction

[0176]

[0177] (4) Results: The main peak area of ​​homogenization for 10 min + ultrasound for 60 min was higher than that of homogenization for 10 min + ultrasound for 15 min and homogenization for 10 min + ultrasound for 30 min. The extraction method of the sample was determined to be shearing at 8000 rpm for 10 min using a homogenizer and ultrasonication for 60 min.

[0178] Example 8

[0179] Method 8 for investigating the specificity of related substances in loxoprofen sodium gel patch:

[0180] (1) Solution preparation:

[0181] Impurity I localization solution: Take about 3.75 mg of impurity I reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0182] Impurity II positioning solution: Take about 1.625 mg of impurity II reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0183] Impurity III localization solution: Accurately weigh approximately 2 mg of the Impurity III reference substance and place it in a 20 ml volumetric flask. Dissolve the solution in methanol and dilute to the mark. Shake well. Accurately measure 5 ml and place it in a 50 ml volumetric flask. Dilute to the mark with methanol and shake well.

[0184] Impurity IV localization solution: Accurately weigh approximately 2 mg of Impurity IV reference substance and place in a 20 ml volumetric flask. Dissolve in an appropriate amount of methanol and dilute to the mark. Shake well. Accurately measure 5 ml and place in a 50 ml volumetric flask. Dilute to the mark with methanol and shake well.

[0185] Impurity V Localization Solution: Accurately weigh approximately 2 mg of the Impurity V reference substance into a 20 ml volumetric flask. Dissolve the solution in methanol and dilute to the mark. Shake well. Accurately measure 5 ml into a 50 ml volumetric flask. Dilute to the mark with methanol and shake well.

[0186] Impurity VI localization solution: Accurately weigh approximately 2 mg of the Impurity VI reference substance and place it in a 20 ml volumetric flask. Dissolve the solution in methanol and dilute to the mark. Shake well. Accurately measure 5 ml and place it in a 50 ml volumetric flask. Dilute to the mark with methanol and shake well.

[0187] Impurity X localization solution: Take about 1.875 mg of impurity X reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0188] Loxoprofen sodium standard solution: Take about 10 mg of loxoprofen sodium reference substance, accurately weigh it, place it in a 100 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0189] Impurity mixed stock solution: Accurately measure 5 ml each of impurity III positioning solution, impurity IV positioning solution, impurity V positioning solution, and impurity VI positioning solution, place them in a 50 ml volumetric flask, dilute to the scale with methanol, and shake well.

[0190] Blank solvent (diluent): methanol.

[0191] System suitability solution: same as the solution in Example 6.

[0192] Blank excipient solution: Take 2.5 g of blank excipient, accurately weigh it, place it in a beaker, add 20 ml of methanol, homogenize it with a homogenizer at 8000 rpm for 10 minutes, seal it and ultrasonicate it for 60 minutes, centrifuge it, take the supernatant, and filter it to obtain the filtrate.

[0193] Excipient control solution: Take a blank patch, scrape out about 2.5g of the paste, accurately weigh it, put it in a beaker, accurately add 50ml of methanol, homogenize it with a homogenizer at 8000 rpm for 10 minutes, seal it and sonicate for 60 minutes, take an appropriate amount of the solution, centrifuge it, take the supernatant, filter it, and take the filtrate.

[0194] Spiked test solution: Take about 2.5 g of the product paste, weigh it accurately, and place it in a beaker. Then accurately add 2 ml each of impurity I localization solution, impurity II localization solution, impurity X localization solution, and 5 ml of impurity mixed stock solution, add 39 ml of methanol, homogenize with a homogenizer at 8000 rpm for 10 minutes, seal the container and sonicate for 60 minutes, take an appropriate amount of solution, centrifuge, take the supernatant and filter to obtain the filtrate.

[0195] Unbroken blank solution: blank solvent.

[0196] Undamaged test sample solution: Take about 2.5g of the product paste, accurately weigh it, place it in a beaker, add 50ml of methanol, homogenize it with a homogenizer at 8000rpm for 10 minutes, seal it and ultrasonicate it for 60 minutes, centrifuge it, take the supernatant, and filter it to obtain the filtrate.

[0197] Undamaged raw material solution: Take about 10 mg of loxoprofen sodium raw material, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0198] Undamaged blank excipient solution: Take 2.5 g of blank excipient, accurately weigh it, place it in a beaker, and prepare it in the same way as the undamaged test sample.

[0199] Acid-destroyed test solution: Take about 2.5g of the product paste, accurately weigh it, put it in a beaker, add 1ml of 1mol / L hydrochloric acid solution, incubate in a 60℃ water bath for 2 hours, let it cool to room temperature, add an appropriate amount of 1mol / L sodium hydroxide solution to neutralize it, add 48ml of methanol, homogenize it with a homogenizer at 8000rpm for 10 minutes, seal the container and sonicate for 60 minutes, centrifuge to take the supernatant, and filter to take the filtrate.

[0200] Acid-destroyed blank excipient solution: 2.5 g of blank excipient, accurately weighed, placed in a beaker, and prepared in the same way as the acid-destroyed test sample.

[0201] Acid-destroyed raw material solution: Take about 10 mg of loxoprofen sodium raw material, accurately weigh it, place it in a stoppered test tube, add 1 ml of 1 mol / L hydrochloric acid solution, and place it in a 60°C water bath for 2 hours. Cool it to room temperature, add an appropriate amount of 1 mol / L sodium hydroxide solution to neutralize it, add methanol to dissolve it and dilute it to 20 ml, and shake it well.

[0202] Alkali-destroyed test solution: Take about 2.5 g of the product paste, accurately weigh it, put it in a beaker, add 1 ml of 1 mol / L sodium hydroxide solution, incubate in a 60°C water bath for 2 hours, let it cool to room temperature, add an appropriate amount of 1 mol / L hydrochloric acid solution to neutralize it, add 48 ml of methanol, homogenize it with a homogenizer at 8000 rpm for 10 minutes, seal the container and sonicate for 60 minutes, centrifuge to take the supernatant, and filter to take the filtrate.

[0203] Alkali-destroyed blank excipient solution: Take 2.5 g of blank excipient, accurately weigh it, place it in a beaker, and prepare it in the same way as the alkali-destroyed test sample.

[0204] Alkali-destroyed raw material solution: Take about 10 mg of loxoprofen sodium raw material, accurately weigh it, place it in a stoppered test tube, add 1 ml of 1 mol / L sodium hydroxide solution, and incubate in a 60°C water bath for 2 hours. Cool it to room temperature, add an appropriate amount of 1 mol / L hydrochloric acid solution to neutralize it, add methanol to dissolve it and dilute it to 20 ml, and shake it well.

[0205] Oxidatively damaged test solution: Take 2.5 g of the product paste, accurately weigh it, place it in a beaker, add 1 ml of 30% hydrogen peroxide solution, and place it in a 60°C water bath for 2 hours. Let it cool to room temperature, add 49 ml of methanol, and homogenize it with a homogenizer at 8000 rpm for 10 minutes. Seal the beaker and ultrasonicate for 60 minutes. Centrifuge to obtain the supernatant and filter to obtain the filtrate.

[0206] Oxidatively damaged blank excipient solution: Take 2.5 g of blank excipient, accurately weigh it, place it in a beaker, and prepare it in the same way as the oxidatively damaged test sample.

[0207] Oxidatively damaged raw material solution: Take 10 mg of loxoprofen sodium raw material, accurately weigh it, place it in a stoppered test tube, add 1 ml of 30% hydrogen peroxide solution, incubate in a 60°C water bath for 2 hours, cool to room temperature, dissolve it in methanol and dilute to 20 ml, and shake well.

[0208] High-temperature damaged test solution: Take 2.5 g of the product paste, accurately weigh it, place it in a beaker, and place it in a 100°C water bath for 2 hours. Let it cool to room temperature, add 50 ml of methanol, and homogenize it with a homogenizer at 8000 rpm for 10 minutes. Seal the beaker and ultrasonicate for 60 minutes. Centrifuge to obtain the supernatant and filter to obtain the filtrate.

[0209] High-temperature destroyed blank excipient solution: Take 2.5 g of blank excipient, accurately weigh it, place it in a beaker, and prepare it in the same way as the high-temperature destroyed test sample.

[0210] High-temperature-damaged raw material solution: Take 10 mg of loxoprofen sodium raw material, accurately weigh it, place it in a stoppered test tube, and place it in a 100°C water bath for 2 hours. Cool it to room temperature, dissolve it in methanol and dilute it to 20 ml, and shake it well.

[0211] Take 10 mg of loxoprofen sodium raw material, accurately weigh it, and place it in a stoppered test tube; take 2.5 g of this product paste, 2.5 g of blank excipient, and 2.5 g of reference preparation, accurately weigh them, and place them in beakers respectively. Place them under light intensity of 4500Lx±500Lx and ultraviolet light of 90μw / cm2 for 3 days, and then take them out.

[0212] Light-damaged test solution: Take the paste beaker after light exposure, add 50 ml of methanol, homogenize with a homogenizer at 8000 rpm for 10 minutes, seal and sonicate for 60 minutes, centrifuge to obtain the supernatant, and filter to obtain the filtrate.

[0213] Light-damaged blank excipient solution: Take the blank excipient beaker after illumination and prepare it in the same way as the light-damaged test sample.

[0214] Light-damaged raw material solution: Take a stoppered test tube of the light-irradiated loxoprofen sodium raw material, add solvent to dissolve and dilute to 20 ml, and shake well.

[0215] (2) Chromatographic conditions: Same as Example 6.

[0216] (3) Determination: Accurately measure blank solvent, each impurity location solution, blank excipient solution, system suitability solution, undamaged blank excipient solution, test solution, raw material solution, acid-damaged blank excipient solution, test solution, raw material solution, alkali-damaged blank excipient solution, test solution, raw material solution, high-temperature-damaged blank excipient solution, test solution, raw material solution, light-damaged blank excipient solution, test solution, raw material solution, and oxidative-damaged blank excipient solution, test solution, raw material solution, respectively, and inject them into a liquid chromatograph to record the chromatogram. The data are shown in Tables 2 and 3 below:

[0217] Table 2: Summary of Degradation Tests - Raw Materials

[0218]

[0219]

[0220] Table 3 Degradation test summary - test samples

[0221]

[0222]

[0223] (4) Results: The blank solvent, blank excipients, and other components in the test sample did not interfere with the test. Under various degradation conditions, loxoprofen sodium was unstable under alkaline and oxidative conditions, but relatively stable under acid, high temperature, and light conditions. This method has good specificity.

[0224] Example 9

[0225] Method 9 for investigating the solution stability of related substances in loxoprofen sodium gel patch:

[0226] (1) Solution preparation:

[0227] Blank solvent: methanol.

[0228] Impurity I stock solution: Take about 3.75 mg of the impurity I reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0229] Impurity II stock solution: Take about 1.625 mg of impurity II reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve and dilute to the scale, and shake well.

[0230] Impurity III stock solution: Take about 2 mg of impurity III reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0231] Impurity IV stock solution: Take about 2 mg of impurity IV reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0232] Impurity V stock solution: Take about 2 mg of impurity V reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0233] Impurity VI stock solution: Take about 2 mg of impurity VI reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0234] Impurity X stock solution: Take about 1.875 mg of the impurity X reference substance, accurately weigh it, place it in a 10 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0235] Impurity mixed stock solution: Accurately measure 5 ml each of impurity III stock solution, impurity IV stock solution, impurity V stock solution, and impurity VI stock solution, place them in a 50 ml volumetric flask, dilute to the scale with methanol, and shake well.

[0236] Reference solution: Accurately add 2 ml each of impurity I stock solution, impurity II stock solution, impurity X stock solution, and 5 ml of impurity mixed stock solution, place in a 50 ml volumetric flask, dilute to the scale with methanol, and shake well.

[0237] Stock solution of spiked test sample: Take about 2.5 g of the product paste, weigh it accurately, and place it in a beaker. Then accurately add 2 ml each of impurity I stock solution, impurity II stock solution, impurity X stock solution, and 5 ml of impurity mixed stock solution, add 39 ml of methanol, homogenize with a homogenizer at 8000 rpm for 10 minutes, seal the container and sonicate for 60 minutes, take an appropriate amount of solution, centrifuge, take the supernatant and filter to obtain the filtrate.

[0238] 1% self-control solution: Accurately measure 2 ml of the spiked test solution, place it in a 200 ml volumetric flask, dilute to the mark with methanol, and shake well.

[0239] (2) Chromatographic conditions: Same as Example 6.

[0240] (3) Determination: At room temperature, accurately measure 20 μl of each of the reference solution, spiked test solution, and 1% self-control solution at different times, inject them into a liquid chromatograph, and record the chromatogram. The data are shown in Tables 4 and 5 below:

[0241] Table 4 Summary of Stability Tests—Reference Solution, 1% Self-Control Solution

[0242]

[0243]

[0244] Table 5 Stability test summary - spiked test solution

[0245]

[0246] (4) Results: Under room temperature conditions, the reference solution, 1% self-control solution, and spiked test solution were placed for 60 hours. The ratio of the peak area of ​​impurities to the main component and the 0-hour value met the requirements within 60 hours, indicating that the reference solution, 1% self-control solution, and spiked test solution were stable within 60 hours.

[0247] Example 10

[0248] Durability assessment method for related substances of loxoprofen sodium gel patch 10:

[0249] (1) Solution preparation:

[0250] Impurity III stock solution: Take about 2 mg of impurity III reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0251] Impurity IV stock solution: Take about 2 mg of impurity IV reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0252] Impurity V stock solution: Take about 2 mg of impurity V reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0253] Impurity VI stock solution: Take about 2 mg of impurity VI reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0254] Impurity VII stock solution: Take about 2 mg of impurity VII reference substance, accurately weigh it, place it in a 20 ml volumetric flask, add an appropriate amount of methanol to dissolve it and dilute it to the scale, and shake well.

[0255] Impurity mixed stock solution: Take about 7.5 mg of impurity I reference substance, about 3.25 mg of impurity II reference substance, and about 3.75 mg of impurity X reference substance, accurately weigh them, and place them in a 50 ml volumetric flask. Accurately add 5 ml each of impurity III stock solution, impurity IV stock solution, impurity V stock solution, and impurity VI stock solution. Add appropriate amount of methanol to dissolve and dilute to the scale, and shake well.

[0256] Mixed excipient solution: Take 750 mg of glycerol, 12.5 mg of peppermint oil, 50 mg of crotamiton, and 30 mg of tartaric acid, accurately weigh them, place them in a 50 ml volumetric flask, add methanol and ultrasonically dissolve them and dilute to the scale, shake well, centrifuge to obtain the supernatant, and filter to obtain the filtrate.

[0257] For spiked test solution: Take one tablet of this product, remove the film, scrape out 1g of the paste, accurately weigh it, and place it in a beaker. Then accurately add 2ml of the impurity mixed stock solution and 18ml of methanol. Homogenize using a homogenizer at 8000rpm for 10 minutes. Seal the container and sonicate for 60 minutes. Centrifuge, remove the supernatant, and filter to obtain the filtrate. (Prepare two in parallel)

[0258] 1% self-control solution: Accurately measure 2 ml of each spiked test solution, place it in a 200 ml volumetric flask, dilute to the scale with solvent, and shake well.

[0259] (2) Chromatographic conditions: Same as Example 6.

[0260] The parameters are changed as follows:

[0261] Change the column temperature, keeping other conditions unchanged:

[0262] ① Column temperature 19℃; ② Column temperature 21℃

[0263] Changing the flow rate, other conditions remain unchanged:

[0264] ① Flow rate 0.8ml / min; ② Flow rate 1.0ml / min

[0265] Change the pH value of mobile phase A, keeping other conditions unchanged:

[0266] ①pH=2.8;②pH=3.0

[0267] (3) Determination: Accurately measure blank solvent, system suitability solution, spiked test solution, and 1% self-control solution, inject them into the liquid chromatograph, and record the chromatogram. The data are shown in Tables 6, 7, and 8 below:

[0268] Table 6 Durability test summary - separation

[0269]

[0270] Table 7 Durability test summary table-1

[0271]

[0272] Table 8 Durability test summary table-2

[0273]

[0274]

[0275] As can be seen from the data in the table above, the separation of each impurity is good with minimal changes in column temperature, flow rate, and mobile phase pH. The number of impurities detected in the test solution is consistent under all conditions, and the changes in known impurities and single unknown impurities meet the requirements, indicating that this method is highly robust. The method described in the present invention has a low wavelength and many impurity peaks in the air-assisted solution, and these chromatographic conditions can significantly improve its separation.

Claims

1. A method for detecting related substances in loxoprofen sodium gel patch, It is characterized in that The following steps are involved: High performance liquid chromatography was used to quantitatively detect the related substances in loxoprofen sodium gel patch; HPLC conditions included: Chromatographic column: octadecylsilane bonded silica gel as filler; Mobile phase A: 0.02 mol / L sodium dihydrogen phosphate solution; Mobile phase B: acetonitrile; Flow rate: 0.8~1.0ml / min; Detection wavelength: 222nm; Diluent: methanol.

2. the detection method of loxoprofen sodium gel patch related substances according to claim 1, It is characterized in that The gradient elution method was used, and the elution procedure was as follows:

3. the detection method of loxoprofen sodium gel patch related substances according to claim 1, It is characterized in that The related substances include: impurity I: 6-(4-(1-carboxyethyl)phenyl)-5-oxohexanoic acid; impurity II: 2,3-dihydroxypropyl 2-{4-[(2-cyclopentanone)methyl]phenyl}propionate; impurity X: 2-(4-{[2-(hydroxymethyl)-1,4-dioxaspiro[4.4]nonane-6-yl]methyl}phenyl)propionic acid; impurity III: 2-(4-acetylbenzyl)cyclopentanone; impurity IV: 2-(4-formylphenyl)propionic acid; impurity V: 4-(1-carboxyethyl)benzoic acid; impurity VI: 6-[4-(1-carboxyethyl)phenyl]-6-oxohexanoic acid; impurity VII: sodium 2-[4-(5-carboxy-2-hydroxypentyl)phenyl]propionate.

4. the detection method of loxoprofen sodium gel patch related substances according to claim 3, It is characterized in that Inject the system suitability solution and the test solution into the liquid chromatograph respectively and record the chromatogram. The system suitability solution and the test solution are prepared as follows: Take loxoprofen sodium reference substance, impurity I, impurity II, impurity III, impurity IV, impurity V, impurity VI, impurity VII, and impurity X reference substances, add methanol to dissolve by ultrasonication, and then dilute to prepare a solution containing 0.5 mg of loxoprofen sodium, 15 μg of impurity I, 6.5 μg of impurity II, 2.5 μg of impurity III, impurity IV, impurity V, impurity VI, impurity VII, and 7.5 μg of impurity X per 1 ml; as the system suitability solution; Take about 2.5g of the paste to be tested, weigh it accurately, put it in a beaker, add 50ml of methanol, homogenize it with a homogenizer at 8000rpm for 10 minutes, seal it and ultrasonicate it for 60 minutes, centrifuge it to take the supernatant, and then filter it to take the filtrate.

5. the detection method of loxoprofen sodium gel patch related substances according to claim 1, It is characterized in that Dilute the test solution 100 times with diluent to prepare a 1% self-control solution.

6. The detection method of loxoprofen sodium gel patch related substances according to claim 1, It is characterized in that The mobile phase A was prepared by taking 2.4 g of sodium dihydrogen phosphate, diluting it to 1000 ml with water, and adjusting the pH value to 2.9±0.1 with phosphoric acid.

7. The detection method of loxoprofen sodium gel patch related substances according to claim 1, It is characterized in that Record the chromatogram, measure using the self-control method, and calculate the content of individual impurities and total impurities.

8. The detection method of loxoprofen sodium gel patch related substances according to claim 1, It is characterized in that The calculation method of individual impurities and total impurities is: Single impurity % = single impurity peak area / control peak area * 1%; Total impurities % = sum of impurity peak areas / control peak area*1%.

9. The detection method of loxoprofen sodium gel patch related substances according to claim 1, It is characterized in that The injection volume was 20 μl.

10. The method for detecting related substances of loxoprofen sodium gel patch according to claim 1, It is characterized in that The column temperature is 19-21°C.

Citation Information

Patent Citations

  • Loxoprofen sodium compound and pharmaceutical composition thereof

    CN103333064A

  • Loxoprofen sodium related substance detection method

    CN115236255A

  • Loxoprofen-containing patch and manufacturing method thereof

    CN116916906A

  • Content for loxoprofen sodium containing soft capsules, and soft capsule pharmaceutical preparation containing the same

    JP2014131996A